explore -WSS

explore

author：hotspot 2025-09-03 03:45:10 - browse：95941

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Just how powerful is the placebo effect?

entertainment

Wikipedia

WSS

Complete sequence of Y chromosome published for first time

2024 GOP presidential candidates spar over abortion in debate

Biotech incubator Curie.Bio graduates its first startup

2024 GOP presidential candidates spar over abortion in debate

HPV cancer vaccine study demonstrates efficacy

The new shift in health care is toward less care

hotspot

explore

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

White House calls on federal agencies to crack down on AI abuses

DIEP, the 'gold standard' of breast reconstruction, is under threat

Appeals court upholds limits to abortion pill

Novavax promises a turnaround & Lilly roils the obesity market

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Continuity nursing helped my family in our darkest PICU moments

Psilocybin's anti

Sports medicine is finally prioritizing gender equality

What do new weight loss drugs mean for bariatric surgery?

leisure time

Medicare solvency divides Republicans at the presidential debate

Excited delirium, Elijah McClain, and emergency physicians

FDA panel gives mixed vote on blood pressure devices

In science, is the line between industry and academia shifting?

AstraZeneca challenges Medicare drug negotiation program

Diversify hospital leadership teams to protect BIPOC patient health

focus

entertainment

Wikipedia

explore